# MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
Canonical URL: https://biopharmsignal.com/news/MXCT/maxcyte-unveils-expert-dtxtm-a-96-well-electroporation-platform-to-accelerate-discovery
Ticker: MXCT
Company: MaxCyte
Source: MaxCyte
Published: 2026-02-24 13:05 EST
Original Source URL: https://investors.maxcyte.com
## Summary

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of

## Article Body
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of
## Recent Company News
- 2026-05-12 20:06 EST — [MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance) — Source: MaxCyte
- 2026-04-29 20:05 EST — [MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026](https://biopharmsignal.com/news/MXCT/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026) — Source: MaxCyte
- 2026-03-31 20:05 EST — [MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MXCT/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: MaxCyte
- 2026-03-24 20:05 EST — [MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance) — Source: MaxCyte
- 2026-03-23 12:05 EST — [MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer](https://biopharmsignal.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer) — Source: MaxCyte
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)